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Abstract: Encrusted cystitis is a subtype of chronic cystitis characterized by multiple 
calciﬁ  cations in the form of plaques located in the interstitium of the urinary bladder mucosa 
and frequently associated with mucosal ulcers. It is a very rare disease of controversial etiology. 
Our transmission electron microscopy of the calciﬁ  ed plaques of encrusted cystitis has revealed 
that the smallest formed particles (elementary units) of these calciﬁ  cations are electron-dense 
shells surrounding an electron lucent core, diagnostic of calcifying nanoparticles (previously 
called nanobacteria). We pioneer the notion that calcifying nanoparticles are the causative agents 
of encrusted urinary bladder cystitis.
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Introduction
Encrusted cystitis is a very rare form of chronic cystitis. Calciﬁ  ed plaques composed of 
calcium salts including phosphate, carbonate, and ammonium-magnesium salts  in the blad-
der mucosa accompanied with inﬂ  ammation and ulcerations characterize pathologically 
encrusted cystitis. Despite its increasing incidence in nineties, especially in immune-
depressed patients and renal transplant recipients (Meria et al 1998), according to a 
PubMed search, by spring 2008, only 60 patients have been reported in 60 published 
articles, mainly single case reports. Etiology of this rare entity, which is characterized by 
calciﬁ  cations in the urinary bladder wall, is presently controversial. A few hypotheses 
exist to explain this phenomenon but are difﬁ  cult to prove. The most popular of them 
proposes combined action of mucosal alterations (lesion of any type) and microorgan-
isms that split urea forming ammonia and thus creating an alkaline environment leading 
to the disease by precipitation of calcium salts (Russell 1901). Corynebacterium group 
D2 (Fernandez Natal et al 1992), Escherichia coli (Romero Perez et al 1992), Streptoc-
cocus hemolyticus, S. viridians, and Proteus (Jameson 1966) species were denoted as 
the most frequent culprits. Calcifying nanoparticles (previously called nanobacteria) 
are self-propagating, cultivable macromolecular complexes (Kajander 2006) generally 
regarded as bacteria but with a lack of deﬁ  nitive genomic proof. The deﬁ  ning char-
acteristic of calcifying nanoparticles (nanobacteria) is their outer envelope composed 
of calcium phosphate that presents on transmission electron microscope images as an 
electron-dense shell surrounding a translucent central core. The name is derived from 
the very small size of these nanoparticles, which varies from 50 nanometers to 500 
nanometers (nm). Calcifying nanoparticles (nanobacteria) are the smallest (50–500 nm) 
cultivable replicating agents on earth, which were isolated from bovine and human 
blood for the ﬁ  rst time by Kajander and colleagues (1997) in the last decade of the 
20th century. The most important characteristic of nanobacteria is that they produce 
carbonate apatite on their cell envelope (Kajander and Çiftçioglu 1998) from soluble 
calcium and phosphorus at physiologic concentrations and conditions. Kajander’s 
discovery initiated further studies and nanobacteria have been implicated in the International Journal of Nanomedicine 2008:3(3) 386
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wide array of human diseases associated with calciﬁ  cations 
including: kidney stone formation (Çiftçioglu et al 1999), 
valvular calciﬁ  cations (Jelic et al 2004; Miller et al 2004), 
psammoma bodies seen in ovarian cancer (Hudelist et al 
2004), calciﬁ  ed atherosclerotic vascular plaques (Miller et al 
2004; Puskas et al 2005), cholelithiasis (Wen et al 2005), 
microcalciﬁ  cation in breast cancer (Altundag et al 2006), 
calciﬁ  c aortic valve stenosis (Jelic et al 2007; Bratos-Perez 
et al 2008), calciﬁ  cations of placental villi (Agababov et al 
2007), and Randall’s plaque (Çiftçioglu et al 2008). The 
etiologic role of nanobacteria in kidney stone formation 
was conﬁ  rmed in a small study (Garcia-Cuerpo et al 2000) 
when nephrolithiais in rats resulted from intrarenal injection 
of nanobacteria that were previously isolated from kidney 
stones. Bratos-Perez and colleagues (2008) successfully cul-
tured self-replicating calcifying nanoparticles from the aortic 
valves of patients with calciﬁ  c aortic stenosis. Despite all 
the above, the concept of nanobacteria is still controversial. 
Some authors interpret nanosize calciﬁ  cations as precipita-
tion of calcium salts on macromolecules (Cisar et al 1999), 
or on protein fetuin (Raoult et al 2008) and these and some 
other authors doubt the mere existence of nanobacteria as 
living microorganisms (Abott 1999; Urbano and Urbano 
2007). This is partially due to the fact that genomic structure 
of nanobacteria has not yet been elucidated. For this reason 
Kajander (2006) suggested changing the name of nanobac-
teria to calcifying nanoparticles, while emphasizing that 
they are self-propagating, cultivable, and infectious agents. 
Recently Mathew and colleagues (2008) documented that 
calcifying nanoparticles were self-replicators in physiological 
conditions and not simple crystals of precipitated inorganic 
apatite. We have found evidence for an association between 
calcifying nanoparticles and encrusted cystitis.
Case report
The patient is a 43-year-old man, a heavy smoker (3–4 packs 
a day for over 10 years) who presented with complaints of 
hematuria and low back pain. He was found to have multiple 
recurring papillary noninvasive urothelial (transitional) 
cell carcinomas at multiple bladder sites grade 1 and grade 
2 (in a scale 1–4) that were completely removed during a 
6-month period. He had three separate transurethral resections 
of the tumors performed approximately every three months. 
After the second resection (July 2006) a single instillation 
of 40 milligrams of mitomycin C was administered. Four 
months later he received six courses of Bacillus Calmette-
Guerin (BCG) over a six-week therapy to prevent bladder 
tumor recurrence per current recommended guidelines. 
Calcium and creatinine blood concentrations were normal 
9.2 mg/dl and 0.7 mg/dl, respectively. The patient’s urine 
did not smell of ammonia. The urine was acidic with a pH 
of 5. The speciﬁ  c gravity was 1.019. Nitrites were negative 
and sediment showed 3 erythrocytes and 23 leukocytes. 
Standard (not prolonged) urine culture was negative. The 
patient was not treated with antibiotics or uroantiseptics except 
during cystoscopy procedure to prevent iatrogenic infection. 
Cystoscopy performed 3 months after the second surgery 
and before BCG application identiﬁ  ed the recurrent papillary 
tumor. It also visualized multiple calciﬁ  ed plaques (Figure 1) 
in the bladder dome. These plaques were associated with at 
least two ulcerations that were hard on palpation due to these 
calciﬁ  cations. The larger ulcer was actively bleeding prior to 
any manipulation. The small papillary tumor was extirpated 
and the calciﬁ  cations were removed from the dome piece by 
piece. Repeated bladder biopsy 6 months later showed no evi-
dence of malignancy but encrusted cystitis was still present.
Material and methods
Biopsies of the tumor and of the bladder dome were ﬁ  xed in 
10% buffered formaldehyde neutral solution and embedded 
into parafﬁ  n blocks. Parafﬁ  n blocks were cut on standard 
rotary microtomes with a routine setting of 4 microns. One 
ribbon from each parafﬁ  n block was placed on glass slide in 
order to be stained with hematoxylin and eosin. The staining 
procedure was performed by an automated robotic stainer with 
a line up of solutions as follows: Biocleer-F, absolute alcohol, 
95% and 80% alcohol, Gill’s III Hematoxylin (7 minutes), 
running tap water, 1% acid alcohol, and eosin (1 min), row 
of alcohol solutions, and ﬁ  nally Biocleer-F. After staining the 
glass slide was placed in a xylene rinse to activate the cover 
Figure 1 Calcifying plaques (white arrows) of encrusted cystitis, cystoscopy 
photograph.International Journal of Nanomedicine 2008:3(3) 387
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slip adhesion on the automated cover-slipping machine. Von 
Kossa’s method for calcium staining is based on silver salt 
and was performed as follows: ribbon 6 microns thin was 
cut off parafﬁ  n block by standard rotary microtome and 
placed on glass slide. After deparafﬁ  nization and hydration 
with distilled water the glass slide was placed in 5% silver 
nitrate solution for 60 minutes exposed to ultraviolet lamp. 
After rinsing in distilled water glass slide was placed in 5% 
sodium thiosulfate (hypo) solution for 2 minutes. After rinsing 
in distilled water nuclear and cytoplsmic counterstaining was 
performed in fast red solution (eosin) for 5 minutes. Rinsing 
in distilled water, dehydration in alcohol, clearing in xylene 
and mounting with Permount were ﬁ  nal steps in von Kossa’s 
procedure for calcium staining. Glass slides were examined 
through a light microscope and color photographs were taken. 
Standard procedure for obtaining electron microcope images 
was implemented as follows: the calciﬁ  ed area was cut out 
from the parafﬁ  n block, deparafﬁ  nized before embedding in 
a polymerized block of spur epoxy resin, and cut into 600 to 
900 angstroms thin slices that were stained with uranyl acetate 
stain and lead citrate stain. Transmission electron microscopy 
was performed on a Zeiss model CEM 902 instrument 
manufactured in West Germany.
Results
Light microscopic examination of the hematoxylin and eosin 
stained sections of the tumor showed noninvasive, low-grade 
papillary urothelial carcinoma. Biopsies from the bladder 
ulcers showed encrusted cystitis with an abundance of calci-
ﬁ  cations conﬁ  rmed by von Kossa stain (Figure 2 A-C).
Transmission electron microscopy of the encrusted cys-
titis calciﬁ  cations revealed that the smallest constituents of 
calciﬁ  cations were not amorphous substance or granules but 
formed particles (elementary units of calciﬁ  cations), com-
posed of electron-dense shell rimming a central translucent 
core. They vary in size (Figures 3, 4) from165 nm to 440 nm 
and exhibit the size and spherical-to-ovoid shape diagnostic 
of calcifying nanoparticles/nanobacteria according to the 
relevant literature and our experience. It is easy to notice in 
Figure 3 that merging of the calcifying nanoparticles (like 
stacking of snowballs) forms micron-size calcium aggregates 
(micron-size plaques) measuring about 3 square microns 
Figure 2 Light microscopy composed picture showing encrusted cystitis, magniﬁ  cation 100 ×, hematoxylin and eosin, A-calciﬁ  cations in the interstitium of the urothelial 
mucosa, B-calciﬁ  cations and chronic inﬂ  ammatory cells in the interstitium, C-calcium stained brown by von Kossa stain.International Journal of Nanomedicine 2008:3(3) 388
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that by further merging have ultimately become plaques of 
encrusted cystitis visible by light microscope (Figure 2) and 
naked eye (Figure 1).
Discussion
Our electron microscopic study of the calciﬁ  cations in the 
urinary bladder mucosa of the patient with encrusted cystitis 
revealed that the smallest formed structures, to wit elemen-
tary units of these calciﬁ  cations are electron-dense rings with 
central lucent core diagnostic of calcifying nanoparticles. As 
discussed in length in the introduction, controversy about 
nature of calcifying nanoparticles (previously called nano-
bacteria) will continue in the future.
Encrusted cystitis is a very rare form of cystitis still of 
controversial etiology and thus no standardized therapy 
exists, although the ﬁ  rst of report for cure of an individual 
patient appeared 107 years ago (Russell 1901). Papillary 
urothelial carcinomas in our patient were successfully 
eradicated but removal of calciﬁ  ed plaques was only par-
tial and encrusted cystitis persisted. Prevailing view is that 
Figure 3 Transmission electron microscopy image of encrusted cystitis calciﬁ  cations (magniﬁ  cation 7,000) demonstrating multiple calcifying nanoparticles (some indicated by 
black thin arrows) with the characteristic electron-dense shell (ring structures 165 nm to 440 nm) surrounding a central electron lucent core. A thick black arrow points to 
the micron-size calcium aggregate about 3 square microns.International Journal of Nanomedicine 2008:3(3) 389
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encrusted cystitis is alkaline cystitis due to urea splitting 
bacteria (mainly Corynebacterium group D2). However, it 
was found later (Huget-Perez et al 1999) that not all patients 
with encrusted cystitis have alkaline urine implying that 
other mechanisms for calciﬁ  cations may play role in the 
genesis of encrusted cystitis. Our patient had acidic urine 
with a pH of 5 and standard urine culture (not prolonged) 
for common microorganisms showed no growth. It has not 
been documented in the literature that nanobacteria or calci-
fying nanoparticles can split urea. It has been demonstrated 
in vitro (Çiftçioglu et al 2008) that nanobacteria (calcifying 
nanoparticles) were inhibited by tetracycline, nitrofurantoin, 
trimethoprim, trimethoprim-sulfamethoxazole, and ampi-
cillin at levels achievable in serum and urine. Our patient 
was not treated with any of these drugs. Encrusted cystitis 
has also been reported after the intravesical application of 
BCG (Spirnak et al 1993) or mitomycin C (Alter and Malek 
1987) for the treatment of bladder carcinoma. Our patient 
developed encrusted cystitis before BCG application. Since 
the ﬁ  rst report by Alter and Malek (1987), only 6 additional 
cases of intravesical calciﬁ  cations after local application of 
mitomycin C were reported, it is unlikely that intravesical 
Figure 4 Calcyifying nanoparticle (280 nm × 230 nm). Transmission electron microscopy image (magniﬁ  cation 50,000) presenting characteristic electron-dense shell surrounding 
an electron lucent core.International Journal of Nanomedicine 2008:3(3) 390
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instillation of this cytostatic drug in our patient caused 
encrusted cystitis but it cannot be totally excluded. At this 
point in time, when nature of calcifying nanoparticles is 
unresolved and their bacterial structure uncertain, it is not 
warranted to speculate that mitomycin C facilitated infection 
with calcifying nanoparticles/nanobacteria. We have revealed 
by electron microscopic study calcifying nanoparticles in the 
calciﬁ  cations of the encrusted cystitis. From this ﬁ  nding we 
have inferred that calcifying nanoparticles are associated 
with encrusted cystitis and are quite possibly the causative 
agents of this very rare disease. At this point in time with 
scant knowledge of pathogenesis and epidemiology of cal-
cifying nanoparticles, a discussion about the mode of infec-
tion or their access to bladder mucosa is premature. Further 
studies are necessary in order to conﬁ  rm whether calcifying 
nanoparticles are causative agents of encrusted cystitis or 
only its pathologic marker.
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